...
首页> 外文期刊>Molecular medicine reports >pH-sensitive microemulsion-based gels for removal of colonic ammonia: A novel preventative oral preparation for hepatic encephalopathy in rats
【24h】

pH-sensitive microemulsion-based gels for removal of colonic ammonia: A novel preventative oral preparation for hepatic encephalopathy in rats

机译:pH敏感的微乳液基凝胶去除结肠氨:大鼠肝性脑病的新型预防性口服制剂

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Microemulsions with limited stability in mimetic gastrointestinal environments have previously demonstrated potential for the effective removal of ammonia from artificial colonic fluid. Specialized pH-sensitive microemulsion-based gels for the removal of colonic ammonia (MBG-RCA), however, possess relative stability in the gastrointestinal (GI) tract of normal rats, indicating potential use in in vivo applications. An investigation of the effects of oral MBG-RCA was conducted in order to evaluate the reduction of intestinal ammonia and the prevention of hepatic encephalopathy (HE) in rat models. Eighty rats were allocated into eight 4-day treatment groups: The HE model (intraperitoneal injection of thioacetamide) group; the high-, medium- and low-dose MBG-RCA therapeutic groups (15, 10 and 5 ml/kg MBG-RCA, respectively); and the normal, blank, lactulose and acetic acid control groups, each of which received daily treatment administration. Oral MBG-RCA effects were identified using behavioral monitoring observed by an infrared night vision supervisory control system, electroencephalograms, blood ammonia levels, intestinal ammonia levels, liver functionality and pathological observation. High- and medium-dose oral administrations of MBG-RCA significantly decreased the blood and intestinal ammonia levels (P<0.05), improved liver functionality and reduced the clinical manifestations of HE in rats. MBG-RCA demonstrated high clearance of rat colonic ammonia while maintaining sufficient stability in the GI tract, indicating the potential for the development of new clinically relevant oral preparations for the prevention of HE. Additionally, such preparations are advantageous in that ammonia is eliminated without the production of potentially harmful metabolic byproducts.
机译:在模拟胃肠道环境中具有有限稳定性的微乳剂先前已经证明了从人工结肠液中有效去除氨的潜力。但是,用于去除结肠氨气(MBG-RCA)的基于pH值的基于微乳化剂的专用凝胶在正常大鼠的胃肠道(GI)中具有相对稳定性,表明其在体内应用中具有潜在用途。为了评估大鼠模型中肠氨的减少和肝性脑病(HE)的预防,对口服MBG-RCA进行了研究。将80只大鼠分为8个为期4天的治疗组:HE模型(腹膜内注射硫代乙酰胺)组;和高,中,低剂量MBG-RCA治疗组(分别为15、10和5 ml / kg MBG-RCA);正常对照组,空白对照组,乳果糖和乙酸对照组,每个对照组均接受每日治疗。使用红外夜视监控系统观察到的行为监测,脑电图,血氨水平,肠氨水平,肝功能和病理观察来鉴定口服MBG-RCA的作用。大剂量和中等剂量的MBG-RCA口服可显着降低大鼠的血液和肠道氨水平(P <0.05),改善肝功能并降低HE的临床表现。 MBG-RCA证明了大鼠结肠氨的高清除率,同时在胃肠道中保持足够的稳定性,这表明开发预防HE的新型临床相关口服制剂的潜力。另外,这样的制剂的优点在于消除了氨,而没有产生潜在有害的代谢副产物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号